Abstract
Maspin is a novel serine protease inhibitor differentially expressed in several types of human cancers. Accumulated evidence indicates that maspin plays a tumor suppressive role at the steps of tumor growth, invasion, tumor-induced extracellular matrix remodeling and angiogenesis, and tumor metastasis. Several recent studies also suggest that maspin plays a role in restoring a more differentiated phenotype and enhances tumor cell sensitivity to drug-induced apoptosis. To date, the underlying molecular mechanisms of maspin remain elusive. This review is intended to summarize research progress made in several areas with a focus on whether maspin acts as a serine protease inhibitor. Towards the potential clinical application of maspin in anti-cancer therapies, this review also discusses the current challenges and future research directions.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Zou, Z., Anisowicz, A., Hendrix, M. J., Thor, A., Neveu, M., Sheng, S., Rafidi, K., Seftor, E., and Sager, R., 1994, Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science, 263:526–529.
Zhang, M., Sheng, S., Maass, N., and Sager, R., 1997, mMaspin: the mouse homolog of a human tumor suppressor gene inhibits mammary tumor invasion and motility. Mol Med, 3:49–59.
Umekita, Y., Hiipakka, R. A., and Liao, S., 1997, Rat and human maspins: structures, metastatic suppressor activity and mutation in prostate cancer cells. Cancer Lett, 113: 87–93.
Bartuski, A. J., Kamachi, Y., Schick, C, Overhauser, J., and Silverman, G. A., 1997, Cytoplasmic antiproteinase 2 (PI8) and bomapin (PI10) map to the serpin cluster at 18q21.3. Genomics, 43:321–328.
Schneider, S. S., Schick, C., Fish, K. E., Miller, E., Pena, J. C., Treter, S. D., Hui, S. M., and Silverman, G. A., 1995, A serine proteinase inhibitor locus at 18q21.3 contains a tandem duplication of the human squamous cell carcinoma antigen gene. Proc Natl Acad Sci U S A, 92:3147–3151.
Scott, F. L., Eyre, H. J., Lioumi, M., Ragoussis, J., Irving, J. A., Sutherland, G. A., and Bird, P. I., 1999, Human ovalbumin serpin evolution: phylogenic analysis, gene organization, and identification of new PI8-related genes suggest that two interchromosomal and several intrachromosomal duplications generated the gene clusters at 18q21–q23 and 6p25. Genomics, 62:490–499.
Nakashima, T., Pak, S. C., Silverman, G. A., Spring, P. M., Frederick, M. J., and Clayman, G. L., 2000, Genomic cloning, mapping, structure and promoter analysis of HEADPIN, a serpin which is down-regulated in head and neck cancer cells. Biochim Biophys Acta, 1492: 441–446.
Sheng, S., Carey, J., Seftor, E. A., Dias, L., Hendrix, M. J., and Sager, R., 1996, Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells. Proc Natl Acad Sci U S A, 93:11669–11674.
McGowen, R., Biliran, H. Jr., Sager, R., and Sheng, S., 2000, The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin. Cancer Res, 60: 4771–4778.
Pemberton, P. A., Tipton, A. R., Pavloff, N., Smith, J., Erickson, J. R., Mouchabeck, Z. M., and Kiefer, M. C. Maspin is an intracellular serpin that partitions into secretory vesicles and is present at the cell surface. J Histochem Cytochem, 45: 1697–1706, 1997.
Katz, A. B. and Taichman, L. B., 1999, A partial catalog of proteins secreted by epidermal keratinocytes in culture. J Invest Dermatol, 112:818–821.
Shao, Z. M., Nguyen, M., Alpaugh, M. L., O'Connell, J. T., and Barsky, S. H., 1998, The human myoepithelial cell exerts antiproliferative effects on breast carcinoma cells characterized by p21WAF1/CIP1 induction, G2/M arrest, and apoptosis. Exp Cell Res, 24:394–403.
Zhang, M., Shi, Y., Magit, D., Furth, P. A., and Sager, R., 2000, Reduced mammary tumor progression in WAP-TAg/WAP-maspin bitransgenic mice. Oncogene, 19:6053–6058.
Shi, H. Y., Liang, R., Templeton, N. S., and Zhang, M., 2002, Inhibition of breast tumor progression by systemic delivery of the maspin gene in a syngeneic tumor model. Mol Ther, 5:755–761.
Shi, H. Y., Zhang, W., Liang, R., Abraham, S., Kittrell, F. S., Medina, D., and Zhang, M., 2001, Blocking tumor growth, invasion, and metastasis by maspin in a syngeneic breast cancer model. Cancer Res, 61:6945–6951.
Sager, R., Sheng, S., Anisowicz, A., Sotiropoulou, G., Zou, Z., Stenman, G., Swisshelm, K., Chen, Z., Hendrix, M. J., Pemberton, P., et al., 1994, RNA genetics of breast cancer: maspin as paradigm. Cold Spring Harb Symp Quant Biol, 59:537–546.
Biliran, H. J., and Sheng, S., 2001, Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin. Cancer Res, 61:8676–8682.
Odero-Marah, V. A., Khalkhali-Ellis, Z., Chunthapong, J., Amir, S., Seftor, R. E., Seftor, E. A., and Hendrix, M. J., 2003, Maspin regulates different signaling pathways for motility and adhesion in aggressive breast cancer cells. Cancer Biol Ther, 2:398–403.
Seftor, R. E., Seftor, E. A., Sheng, S., Pemberton, P. A., Sager, R., and Hendrix, M. J., 1998, Maspin suppresses the invasive phenotype of human breast carcinoma. Cancer Res, 58:5681–5685.
Sheng, S., Pemberton, P. A., and Sager, R., 1994, Production, purification, and characterization of recombinant maspin proteins. J Biol Chem, 269: 30988–30993.
Zhang, M., Volpert, O., Shi, Y. H., and Bouck, N. Maspin is an angiogenesis inhibitor. Nat Med, 6: 196–199, 2000.
Shi, H. Y., Zhang, W., Liang, R., Kittrell, F., Templeton, N. S., Medina, D., and Zhang, M., 2003, Modeling human breast cancer metastasis in mice: maspin as a paradigm. Histol Histopathol, 18:201–206.
Cher, M. L., Biliran, H. R. Jr., Bhagat, S., Meng, Y., Che, M., Lockett, J., Abrams, J., Fridman, R., Zachareas, M., and Sheng, S., 2003, Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis. Proc Natl Acad Sci USA, 100:7847–7852.
Sheng, S., 2004, The promise and challenge toward the clinical application of maspin in cancer. Frontiers in Bioscience, 9:2733–2745.
Hojo, T., Akiyama, Y., Nagasaki, K., Maruyama, K., Kikuchi, K., Ikeda, T., Kitajima, M., and Yamaguchi, K., 2001, Association of maspin expression with the malignancy grade and tumor vascularization in breast cancer tissues. Cancer Lett, 171:103–110.
Song, S. Y., Lee, S. K., Kim, D. H., Son, H. J., Kim, H. J., Lim, Y. J., Lee, W. Y., Chun, H. K., and Rhee, J. C., 2002, Expression of maspin in colon cancers: its relationship with p53 expression and microvessel density. Dig Dis Sci, 47:1831–1835.
Jiang, N., Meng, Y., Zhang, S., Mensah-Osman, E., and Sheng, S., 2002, Maspin sensitizes breast carcinoma cells to induced apoptosis. Oncogene, 21:4089–4098.
Liu, J., Yin, S., Reddy, N., Spencer, C., and Sheng, S., (in press) 2004, Bax Mediates the apoptosis-sensitizing effect of maspin. Cancer Res.
Zhang, M., Magit, D., Botteri, F., Shi, H. Y., He, K., Li, M., Furth, P., and Sager, R., 1999, Maspin plays an important role in mammary gland development. Dev Biol, 215:278–287.
Nemeth, J. A., Harb, J. F., Barroso, U. Jr., He, Z., Grignon, D. J., and Cher, M. L., 1999, Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone. Cancer Res, 59:1987–1993.
Abraham, S., Zhang, W., Greenberg, N., and Zhang, M., 2003, Maspin functions as tumor suppressor by increasing cell adhesion to extracellular matrix in prostate tumor cells. J Urol, 169:1157–1161.
Ngamkitidechakul, C., Burke, J. M., O'Brien, W. J., and Twining, S. S., 2001, Maspin: synthesis by human cornea and regulation of in vitro stromal cell adhesion to extracellular matrix. Invest Ophthalmol Vis Sci, 42:3135–3141.
Bass, R., Fernandez, A. M., and Ellis, V., 2002, Maspin inhibits cell migration in the absence of protease inhibitory activity. J Biol Chem, 277:46845–46848.
Dokras, A., Gardner, L. M., Kirschmann, D. A., Seftor, E. A., and Hendrix, M. J., 2002, The tumour suppressor gene maspin is differentially regulated in cytotrophoblasts during human placental development. Placenta, 23:274–280.
Ngamkitidechakul, C., Warejcka, D. J., Burke, J. M., O'Brien, W. J., and Twining, S. S., 2003, Sufficiency of the reactive site loop of maspin for induction of cell-matrix adhesion and inhibition of cell. Conversion of ovalbumin to a maspin-like molecule. J Biol Chem, 278:31796–31806.
Lefter, L. P., Sunamura, M., Furukawa, T., Takeda, K., Kotobuki, N., Oshimura, M., Matsuno, S., and Horii, A., 2003, Inserting chromosome 18 into pancreatic cancer cells switches them to a dormant metastatic phenotype. Clin Cancer Res, 9:5044–5052.
Mueller, E., Sarraf, P., Tontonoz, P., Evans, R. M., Martin, K. J., Zhang, M., Fletcher, C., Singer, S., and Spiegelman, B. M., 1998, Terminal Differentiation of Human Breast Cancer through PPAR? Molecular Cell, 1:465–470.
Burgermeister, E., Tencer, L., and Liscovitch, M., 2003, Peroxisome proliferator-activated receptor-gamma upregulates caveolin-1 and caveolin-2 expression in human carcinoma cells. Oncogene, 22:3888–3900.
Khalkhali-Ellis, Z., and Hendrix, M. J., 2003 Nitric oxide regulation of maspin expression in normal mammary epithelial and breast cancer cells. Am J Pathol, 162:1411–1417.
Gettins, P. G., Backovic, M., and Peterson, F. C., 2004, Use of NMR to study serpin function. Methods, 32:120–129.
Gettins, P. G., 2002, Serpin structure, mechanism, and function. Chem Rev, 102:4751–4804.
Zhou, A., Carrell, R. W., and Huntington, J. A., 2001, The serpin inhibitory mechanism is critically dependent on the length of the reactive center loop. J Biol Chem, 276:27541–27547.
Sheng, S., Biliran, J. Jr., and McGowen, R., 2002, Maspin and Pericellular Plasminogen Activation in Cell-Matrix Interaction. In Maspin, ed. Hendrix, M. J.C., 57–67, Landes Bioscience, Georgetown, TX, USA.
Fitzpatrick, P. A., Wong, D. T., Barr, P. J., and Pemberton, P. A., 1996, Functional implications of the modeled structure of maspin. Protein Eng, 9:585–589.
Carl Branden, C., and Tooze, J., 1991, In Introduction to Protein Structure, Garland Publishing, Inc., New York, NY.
Sun, J., Rose, J. B., and Bird, P, 1995, Gene structure, chromosomal localization, and expression of the murine homologue of human proteinase inhibitor 6 (PI-6) suggests divergence of PI-6 from the ovalbumin serpins. J Biol Chem, 270:16089–16096.
Spring, P., Nakashima, T., Frederick, M., Henderson, Y., and Clayman, G., 1999, Identification and cDNA cloning of headpin, a novel differentially expressed serpin that maps to chromosome 18q. Biochem Biophys Res Commun, 264:299–304.
Askew, Y. S., Pak, S. C., Luke, C. J., Askew, D. J., Cataltepe, S., Mills, D. R., Kato, H., Lehoczky, J., Dewar, K., Birren, B., and Silverman, G. A., 2001, SERPINB12 is a novel member of the human ovserpin family that is widely expressed and inhibits trypsin-like serine proteinases. J Biol Chem, 276:49320–49330.
Silverman, G. A., Bartuski, A. J., Cataltepe, S., Gornstein, E. R., Kamachi, Y., Schick, C., and Uemura, Y., 1998, SCCA1 and SCCA2 are proteinase inhibitors that map to the serpin cluster at 18q21.3. Tumour Biol, 19:480–487.
Masumoto, K., Sakata, Y., Arima, K., Nakao, I., and Izuhara, K., 2003, Inhibitory mechanism of a cross-class serpin, the squamous cell carcinoma antigen 1. J Biol Chem, 278:45296–45304.
Carrell, R. W., Stein, P. E., Fermi, G., and Wardell, M. R., 1994, Biological implications of a 3 A structure of dimeric antithrombin. Structure, 2:257–270.
Stein, P. E., and Carrell, R. W., 1995, What do dysfunctional serpins tell us about molecular mobility and disease?. Nat Struct Biol, 2:96–113.
Sheng, S., Truong, B., Fredrickson, D., Wu, R., Pardee, A. B., and Sager, R., 1998, Tissue-type plasminogen activator is a target of the tumor suppressor gene maspin. Proc Natl Acad Sci USA, 95:499–504.
Pemberton, P. A., Wong, D. T., Gibson, H. L., Kiefer, M. C., Fitzpatrick, P. A., Sager, R., and Barr, P. J., 1995, The tumor suppressor maspin does not undergo the stressed to relaxed transition or inhibit trypsin-like serine proteases. Evidence that maspin is not a protease inhibitory serpin. J Biol Chem, 270:15832–15837.
Liu, T., Pemberton, P. A., and Robertson, A. D., 1999, Three-state unfolding and self-association of maspin, a tumor-suppressing serpin. J Biol Chem, 274:29628–29632.
Griffith, M. J., 1983, Heparin-catalyzed inhibitor/protease reactions: kinetic evidence for a common mechanism of action of heparin. Proc Natl Acad Sci USA, 80:5460–5464.
Stahl, A., and Mueller, B. M., 1995, The urokinasetype plasminogen activator receptor, a GPI-linked protein, is localized in caveolae. J Cell Biol, 129:335–344.
Schmitt, M., Harbeck, N., Thomssen, C., Wilhelm, O., Magdolen, V., Reuning, U., Ulm, K., Hofler, H., Janicke, F., and Graeff, H., 1997, Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost, 78:285–296.
Blacque, O. E., and Worrall, D. M., 2002, Evidence for a direct interaction between the tumor suppressor serpin, maspin, and types I and III collagen. J Biol Chem, 277:10783–10788.
Behrendt, N., List, K., Andreasen, P. A., and Dano, K., 2003, The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation. Biochem J, 371:277–287.
Kumei, Y., Morita, S., Shimokawa, H., Ohya, K., Akiyama, H., Hirano, M., Sams, C. F., and Whitson, P. A., 2003, Inhibition of HSP70 and a collagenspecific molecular chaperone (HSP47) expression in rat osteoblasts by microgravity. Ann N Y Acad Sci, 1010:476–480.
O'Reilly, M. S., Pirie-Shepherd, S., Lane, W. S., and Folkman, J., 1999, Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science, 285:1926–1928.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer
About this chapter
Cite this chapter
Sheng, S. (2005). Maspin: A Novel Serine Protease Inhibitor. In: Meadows, G.G. (eds) Integration/Interaction of Oncologic Growth. Cancer Growth and Progression, vol 15. Springer, Dordrecht. https://doi.org/10.1007/1-4020-3414-8_23
Download citation
DOI: https://doi.org/10.1007/1-4020-3414-8_23
Publisher Name: Springer, Dordrecht
Print ISBN: 978-1-4020-3413-8
Online ISBN: 978-1-4020-3414-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)